Read more

September 23, 2019
1 min read
Save

Hair regrowth, PRP for ulcer healing among top dermatology news from last week

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In alopecia areata, combination tofacitinib and oral minoxidil therapy may be superior to tofacitinib alone, according to researchers from Yale University School of Medicine, in the top Healio Dermatology story from last week.

Other popular news included platelet-rich plasma (PRP) for ulcer healing and the characteristics of skin microbiota in patients with rosacea. Read on for the top 5 stories.

 

Tofacitinib plus oral minoxidil promotes hair regrowth in severe alopecia

“Janus kinase inhibitors are emerging as an important therapy for severe alopecia areata and the possibility of increasing efficacy without increasing Janus kinase inhibitor dosage (and immunomodulation and cost of treatment) would be welcome,” Carlos G. Wambier, MD, PhD, and colleagues wrote. Read more.

 

Platelet-rich plasma may facilitate ulcer healing

Platelet-rich plasma, or PRP, appears to yield healing in ulcers as it changes the matrix metalloproteinase and cytokine expression shortly after topical application. Read more.

 

Skin microbiota in rosacea differs from healthy skin

Individuals with rosacea showed changes from that of healthy skin, indicating that more research is warranted to understand the pathophysiology of the disease, according to findings from a case-control study published in American Journal of Clinical Dermatology. Read more.

 

Adapalene/benzoyl peroxide gel reduces atrophic acne scars, lesions up to 48 weeks

After 24 weeks of treatment with adapalene/benzoyl peroxide gel, atrophic acne scarring and lesions were reduced, and results were maintained after 48 weeks of treatment in adult patients. Read more.

 

Topical solution from Aclaris clears warts by day 29 in phase 3 study

Aclaris Therapeutics announced positive results from a phase 3 clinical trial of A-101 45% topical solution, an investigational new drug for the treatment of common warts. Read more.